12:00 AM
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ganetespib: Phase II started

Synta disclosed in its 2Q11 earnings that investigators at the Dana-Farber Cancer Institute began an open-label, U.S. Phase II trial to compare 200 mg/m 2 IV ganetespib given...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >